Thus, inhibitors of P2X7 or strategies aimed at disrupting Ap4A-mediated signaling may hold potential for controlling tumor progression, immune suppression, and therapeutic resistance by modulating purinergic signaling dynamics within the TME. Here, P2RX7 is linked to neoplasm.